Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06507878 · ClinicalTrials.gov registry record
Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
A clinical trial of Thyroid Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 459
- Enrollment target
- 1
- Study location
NCT06507878: Recruiting study of Thyroid Cancer, sponsored by M.D. Anderson Cancer Center.
NCT06507878 is a study of Thyroid Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 459 participants, above the 272-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (69% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06507878, a study of Thyroid Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 459 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatment of this disease, outside of a clinical study.
Conditions Studied
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2034-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06507878
The ClinicalTrials.gov registry entry for NCT06507878 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 459 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 272-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (69% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06507878 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06507878 about?
NCT06507878 is a clinical study titled "Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.". The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatment of this disease, outside of a clinical study.
What is the current status of trial NCT06507878?
This trial is currently recruiting. The enrollment target is 459 participants. The study started on 2024-12-05. Estimated completion is 2034-07-01.
What conditions does trial NCT06507878 study?
This clinical trial studies the following conditions: Thyroid Cancer.
Who is sponsoring clinical trial NCT06507878?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06507878 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.